Skip to main content
OPTUS Pharmaceutical Co., Ltd. logo

OPTUS Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 131030 ISIN · KR7131030009 KO Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2025-11-05 Capital/Financing Update
Country KR South Korea
Listing KO 131030

About OPTUS Pharmaceutical Co., Ltd.

http://optuspharm.com/us/main/index.php

OPTUS Pharmaceutical Co., Ltd. is a specialized pharmaceutical company focused on the research, development, manufacturing, and commercialization of ophthalmic products. The company's primary expertise lies in producing sterile, preservative-free, single-dose (unit-dose) formulations. Its therapeutic portfolio addresses conditions such as dry eye syndrome, keratoconjunctival epithelial disease, bacterial conjunctivitis, and glaucoma. In addition to prescription and over-the-counter pharmaceuticals, the company is expanding into a total eye care model through its OUE& brand, which encompasses nutritional supplements (OUEFIT) and cosmeceuticals (OUELAB). The company operates EU-GMP certified manufacturing facilities and distributes its products globally.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a short announcement about the results of a securities issuance, specifically a third-party allotment of common shares with details on the number of shares issued, amount raised, dates, and listing plans. It is a typical capital/financing update rather than a full financial report or regulatory filing. The length is only 486 characters, indicating it is a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-11-05 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 95% confidence The document is titled '주요사항보고서(유상증자결정)' which translates to 'Material Information Report (Decision on Paid-in Capital Increase)'. It is addressed to the Financial Services Commission and Korea Exchange, indicating a regulatory filing. The content details a decision on a capital increase through third-party allocation, including specifics on the number and type of shares, issuance price, purpose of funds, and related corporate governance matters. There is no comprehensive financial statement or management discussion, but rather a formal announcement of a financing event. The document length is about 4,846 characters, which is relatively short and focused on the capital increase decision. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories. Therefore, the appropriate classification is CAP with high confidence.
2025-10-22 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서(약식)' which translates to 'Report on Large Shareholding Status (Abbreviated)'. It contains detailed information about the number of shares held, changes in shareholding, and related data for a specific company (Optus Pharma Co., Ltd.) and a large shareholder (Korea Securities Finance Corporation). The document includes dates, share quantities, ownership percentages, and reasons for changes in holdings. This matches the description of a 'Major Shareholding Notification' which reports changes in significant share ownership levels. The document is over 6,000 characters and contains substantive data, not just an announcement or certification. Therefore, it fits the category 'Major Shareholding Notification' (Code: MRQ).
2025-10-10 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is titled '자기주식처분결과보고서' which translates to 'Report on Disposal of Treasury Shares'. It details the disposal of treasury shares by the company Optus Pharm, including dates, quantities, prices, and post-disposal holdings. The document is only 1900 characters long, indicating it is a concise report focused on a specific transaction rather than a comprehensive financial report. This matches the description of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2025-10-02 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is titled '주요사항보고서(자기주식 처분 결정)' which translates to 'Material Fact Report (Decision on Disposal of Treasury Shares)'. It is addressed to the Financial Services Commission and Korea Exchange, indicating a regulatory filing. The content details the decision to dispose of treasury shares, including quantities, prices, dates, and methods of disposal. There is no financial statement or comprehensive financial analysis present, nor is it an announcement of a report publication. The document is a specific regulatory disclosure about treasury share disposal, which aligns with the category for reporting transactions involving the company's own shares. Therefore, the appropriate classification is 'Transaction in Own Shares (POS)'. The document length is 2792 characters, which is relatively short but contains detailed transactional information, not just an announcement or certification.
2025-10-01 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Optus Pharmaceuticals' (주식회사 옵투스제약) for the period ending June 30, 2025. It contains detailed financial information, company history, capital structure, and business operations, which fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.